Euros50.2m Schleicher & Schuell deal will give Whatman 16% market share
This article was originally published in Clinica
Whatman's planned purchase of Germany-based Schleicher & Schuell for £34.6m ($63.8m) will give the UK separations company a 16% share of the global lab sciences sector, making it the clear number three behind Millipore and Pall. The integration of Dassel-based S&S will increase Whatman's employee base by some 400 to over 1,110 and expand its sales by around 40%, the combined unit expecting sales in 2005 of some £116m, including £34m from S&S.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.